0.66
+6.15%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vivoryon Therapeutics
Its shares trade on Euronext Amsterdam under the ticker VVY.AS. In the fiscal year to 31 December 2025, it reported a net loss of €8.9m. At that date it held total assets of €7.5m and shareholders' equity of €4.7m.
Vivoryon Therapeutics AG is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt. The firm offers medicines that targets post-translational modifying enzymes. The company focuses on Alzheimer's disease and oncology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Employees
- 16
- Website
- vivoryon.com ↗
Leadership
Pay as last reported
- Dr. Erich PlatzerNon-Executive Independent Chairman of the Board, since 2007€105,000
- Dr. Frank WeberChief Executive Officer, Executive Director, Chief Medical Officer, since 2010€1.1m
- Ms. Anne DoeringChief Financial Officer, Executive Director, since 2023€922,000
- Ms. Julia NeugebauerChief Operating Officer, Executive Officer
- Dr. Michael SchaefferChief Business Officer, Executive Director, since 2018€577,000
- Ms. Charlotte LohmannNon-Executive Independent Director€95,000
- Dr. Claudia RiedlNon-Executive Independent Director€113,000
- Dr. Samir ShahNon-Executive Independent Director€136,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vivoryon Therapeutics NV possesses a robust pipeline of innovative therapeutics, which positions the company favorably within the pharmaceutical industry. Their focus on developing novel drugs targeting protein misfolding diseases, such as Alzheimer's and Parkinson's, demonstrates a strong commitment to addressing unmet medical needs.
- The company has successfully formed strategic partnerships and collaborations with renowned pharmaceutical companies and research institutions. These collaborations provide access to additional resources, expertise, and funding, enhancing Vivoryon's ability to accelerate drug development and expand its portfolio.
Weaknesses
- Vivoryon's therapeutic focus primarily revolves around protein misfolding diseases, such as Alzheimer's and Parkinson's. While targeting niche markets can yield substantial rewards, it also carries the risk of limited market diversification. Dependence on a few specific diseases may leave the company vulnerable to fluctuations in market demand or unexpected challenges within those therapeutic areas.
- Many of Vivoryon's therapeutics are still in the early stages of development, which entails substantial research and development costs, as well as inherent uncertainty regarding efficacy and safety. Early-stage development also means longer timelines before potential revenue generation, posing financial challenges and increasing the risk of setbacks in clinical trials.
Opportunities
- The global prevalence of Alzheimer's and Parkinson's diseases is rising, resulting in a growing demand for effective treatments. Vivoryon Therapeutics NV is well-positioned to meet this demand with its innovative drugs targeting protein misfolding. By capturing a share of this expanding market, the company has a significant opportunity for revenue growth and market leadership.
- As precision medicine continues to advance, tailored therapies for specific patient populations become increasingly feasible. Vivoryon's focus on developing therapies targeting protein misfolding diseases aligns with this trend, allowing the company to potentially offer personalized treatments for patients based on their specific disease mechanisms or genetic profiles.
Threats
- The pharmaceutical industry is highly competitive, with numerous players actively developing drugs for Alzheimer's and Parkinson's diseases. Vivoryon Therapeutics NV faces intense competition from established pharmaceutical companies, as well as emerging biotech firms, requiring continuous innovation and significant investments to stay ahead.
- Developing and commercializing novel therapeutics involves navigating complex regulatory requirements and conducting rigorous clinical trials. Delays or failure in obtaining regulatory approvals or achieving desired clinical trial results can significantly impact Vivoryon's product pipeline, hindering growth prospects and increasing costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.